lymphoma
Conditions
Interventions
test group A:The previous chemotherapy cycle (control cycle) showed chemotherapy-induced thrombocytopenia with a minimum platelet value 100×10^9/L was seen for 3 consecutive days on days 5-10 of rhTPO
test group B:The previous chemotherapy cycle (control cycle) showed chemotherapy-induced thrombocytopenia with a minimum platelet value 100×10^9/L was seen for 3 consecutive days on days 5-10 of rhTPO
Sponsors
Shanxi Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age 18~75 years old, male and female. 2.Meet the diagnostic criteria of diffuse large B-cell lymphoma and peripheral T-cell lymphoma. 3.Patients who clinically need to receive at least three or more consecutive cycles of CHOP chemotherapy regimen, R-CHOP-like chemotherapy regimen. 4.Platelet count minimum <50×109/L or 50×109/L <minimum <75×109/L in the previous chemotherapy cycle. 5.Dose adjustment of the chemotherapy regimen between the control cycle and the control cycle does not exceed ±10%. 6.No obvious abnormality in liver and kidney function (serum urea nitrogen, creatinine, transaminase, bilirubin are =2.5 times of the upper limit of normal). 7.No abnormality in coagulation function (APTT, PT, Fg, TT and D-dimer = 2 times of the upper limit of normal) 8.No grade 3 to 4 cardiac or pulmonary dysfunction according to NCI CTC AE v4.03. 9.Life expectancy is greater than 12 weeks. 10.Patients voluntarily participated in this study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. History of severe allergy to biological agents. 2. Thromboembolic or hemorrhagic disease, or a history of recent thrombosis. 3. History of psychiatric disorders. 4. Pregnancy or lactation, or inability to use contraception during the study. 5. Comorbid acute severe infections. 6. Previous cycle of treatment with TPORA, IL-11 drugs. 7. Other conditions that the investigator believes the patient should not participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with grade III and IV thrombocytopenia, per chemotherapy cycle; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in platelet count, per chemotherapy cycle;Number and dose of platelet transfusions, per chemotherapy cycle;For each cycle of chemotherapy, the lowest value of platelet reduction and the time of occurrence;;Duration of days with platelet counts less than 25 x 10^9/L, 50 x 10^9/L, and 75 x 10^9/L per chemotherapy cycle;;Patient bleeding status per chemotherapy cycle;;Number of days of rhTPO salvage therapy performed, per chemotherapy cycle;;For each cycle of chemotherapy, the total number of days patients were hospitalized;Per chemotherapy cycle, incidence of cardiotoxic adverse events; | — |
Countries
China
Contacts
Public ContactLi Ma
Shanxi Cancer hospital
Outcome results
None listed